Opportunities & Challenges for Decentralizing Cell & Gene Therapy Manufacturing

In by

Spotlight Article

Interview

Steve Goodman

SUPPLY CHAIN MANAGEMENT PART 2: CREATING A LOGISTICS STRATEGY FOR COMMERCIALIZATION

Steve Goodman is the head of drug product manufacturing at bluebird bio, where he oversees production of cellular therapies across their portfolio of products and is accountable for the long-term technology strategy to expand access of these treatments to serve global patient requirements. Before joining bluebird in January 2018, Steve was at GSK where he held a number of roles across research, development, manufacturing and supply chain. These included roles leading cross-functional teams in the design, development and transfer of clinical and commercial chemical manufacturing processes; designing and implementing supply chain strategies for ex vivo and in vivo gene-modified cell therapies as well as for small molecule medicines; and managing manufacturing operations to ensure the safe and efficient supply of important commercial respiratory products to global patients. Most recently he served as Director of Manufacturing and Strategy for the Cell and Gene Therapy unit where he was responsible for the external manufacturing of the entire value chain to support GSK’s ex vivo cellular therapies, and for defining and executing the vector manufacturing strategy. Steve joined GSK in 2002 following a PhD and post-doctoral fellowship in organic synthetic chemistry at Harvard University.

DOI:10.18609/cgti.2018.049
Citation: Cell Gene Therapy Insights 2018; 4(5),485-494.
Open access

This content is restricted to registered users. Click here to Register or Login here.